Rare Diseases Medical Conversation Video

About Rare Diseases Medical Conversation Video

Join medical experts as they discuss their approaches to identifying, treating, and managing rare diseases, like primary biliary cholangitis, neuroendocrine tumors, rare bone diseases, and growth disorders. The conversations also explore the evolving treatment landscape, including exciting innovations in gene therapies and the use of somatostatin analogues. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com

Publisher

COR2ED

Category

education · health & fitness · science

Language

en

Explicit

No

First episode

6 Dec 2023

Latest episode

9 Jun 2026

Latest episodes

10 episodes in the feed.

1. 

   9 Jun 2026

   Think narcolepsy: Why early recognition and referral matter in an evolving treatment landscape

   Join experts Dr Markus Schmidt and Dr Anna Heidbreder as they discuss the importance of early recognition and referral in narcolepsy type 1 (NT1), particularly as new targeted treatments begin to emerge. Key discussion points include: Emerging therapies: How OX2R agonists may transform narcolepsy care, with Phase 3 overporextin data showing significant improvements in wakefulness and cataplexy with no serious AEs reported. Diagnostic red flags: Recognising excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations to help reduce the current 7–10 year delay in diagnosis. Clinical pitfalls: Avoiding common misdiagnoses, such as attributing symptoms to lifestyle-related fatigue in younger patients or sleep apnoea in older adults. Specialist referral: The importance of timely referral for specialist assessment and objective sleep testing to support earlier access to emerging therapies. By identifying these symptom clusters earlier, clinicians may improve long-term outcomes and quality of life for people living with NT1. Key clinical takeaways: New treatment options are emerging: OX2R agonists represent a shift toward targeting the underlying biology of NT1, with the potential to significantly improve patient outcomes Early recognition is critical: Narcolepsy is often under-recognised and misdiagnosed, so clinicians should maintain a high index of suspicion, particularly in patients with excessive daytime sleepiness Act early and refer appropriately: Timely referral to specialists is essential to confirm diagnosis, optimise management, and ensure patients can benefit from current and emerging therapies You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/sleep-connect/programmes/narcolepsy-early-recognition-referral/?media=0 Or watch on YouTube: https://youtu.be/jHgORhjB_lw Follow us on social media: LinkedIn: https://www.linkedin.com/company/sleep-connect/about/ X: https://x.com/SleepConnect_ Instagram: https://www.instagram.com/cor2edmeded This content is intended for healthcare professionals only. This podcast is supported by an Independent Education Grant from Takeda This podcast is developed by cor2ed.com Published May 2026 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

2. 

   7 Nov 2025

   Understanding EP-NEC: Through Diagnosis, Treatment, and Support

   In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers. They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies. Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease. Key clinical takeaways: Unlike NETs, EP-NECs are poorly-differentiated, high-grade, aggressive, and fast-growing cancers with, currently, a poor prognosis While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise Accessing a support network can provide emotional reinforcement and information for patients and their care partners You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0 Or watch on YouTube: https://youtu.be/nfng2s3jSw8 Follow us on social media: LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true X: https://x.com/net_connectinfo/status/1837039277353382012 This podcast is supported by an Independent Education Grant from ITM. This podcast is developed by cor2ed.com Published in November 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

3. 

   17 Sept 2025

   Exploring the role of targeted radiopharmaceutical treatment in NETs

   How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety? In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs. As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy. Key clinical takeaways: Pair the right patient with the right treatment using an understanding of the key clinical studies The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data The best outcomes are achieved through multi-disciplinary collaborations that include the patient Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0 Follow us on social media: LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true X: https://x.com/net_connectinfo This content is intended for healthcare professionals only. This podcast is supported by an Independent Education Grant from ITM. This podcast is developed by cor2ed.com Published September 2025

4. 

   10 Dec 2024

   Short-stature conditions, including SPIGFD

   Dr Andrew Dauber and Dr Marta Ramón Krauel delve into the complexities of SPIGFD, a rare short-stature condition, providing healthcare professionals with valuable insights for accurate diagnosis and effective management.

5. 

   11 Sept 2024

   Neuroendocrine tumours (NETs) – Shared decision-making. Part 1: Patient journey

   In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the importance of communication and collaboration during consultations. This can include how to make a patient feel as comfortable and in control as possible, as well as recognising their goals and concerns. The speakers share their real-life experiences of what makes a good consultation, from the perspectives of both a patient and a physician. They also explore the importance of support networks, individualising treatment, and the impact of NET and NET treatment options in daily life. NETs are complex, rare diseases. Optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. Are you aware of how healthcare practitioners and patients can share decision- making? Or the recent data on how patients prefer to receive treatment? In this first episode of a two-part podcast series, Dr Mohid S Khan and NET patient Sally Jenkins discuss shared decision-making in NET consultations and ways to help the patient in their journey. Prefer to watch and listen? Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/ Watch the full video on YouTube https://youtu.be/YgqrEnSePWg Watch the highlights video on YouTube – [LINK] Follow us on social media LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect

6. 

   11 Sept 2024

   Neuroendocrine tumours (NETs) – Shared decision-making. Part 2: Individualising treatment decisions

   In this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared decision-making, between patient and physician. The speakers discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no standard therapy for patients with NETs. Finally, they look at some of the studies reporting patient preferences, and how the data can be used to inform patient decisions. Prefer to watch and listen? Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/?media=1 Watch the full video on YouTube https://youtu.be/2JYuPhc2jHg Watch the highlights video on YouTube – [LINK] Follow us on social media LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect X: https://x.com/net_connectinfo This content is intended for healthcare professionals only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Medical

7. 

   28 May 2024

   Regional differences in NET: Treatment and future developments

   In the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living with NETs and future developments in the field which may help to improve patient outcomes. The episode includes information on different treatment options and modalities, and well as best practice on identifying which patients may benefit most from particular treatments using available biomarkers. Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center. Prefer to watch as well as listen? Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-2/ (https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-2/) Or go to the video on YouTube: https://youtu.be/zd_JvUmIhFg (https://youtu.be/zd_JvUmIhFg) We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/ (https://nanets.net/) The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. This podcast is developed by cor2ed.com

8. 

   28 May 2024

   Regional differences in NET: Epidemiology, diagnosis, and referral strategies

   In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient pathways, as well as look to future developments. NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional differences can impact these? In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, patient pathways, as well as look to future developments. Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center. Prefer to watch as well as listen? Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-1/ (https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-1/) Or go to the video on YouTube: https://youtu.be/6fKAxS4u-2o (https://youtu.be/6fKAxS4u-2o) We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/ (https://nanets.net/) The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. This podcast is developed by cor2ed.com

9. 

   12 Dec 2023

   Short stature: Severe primary IGF-I deficiency (SPIGFD). Part 2

   Comprehensive biochemical and genetic testing allows for the identification of classical and non-classical forms of primary IGF-I deficiency and can identify overlapping syndromes. Are you updated on the treatment for patients with severe primary IGF-I deficiency? Listen as expert pediatric endocrinologists delve into this rare growth disorder. Join Prof. Helen Storr (Professor and Honorary Consultant in Paediatric Endocrinology at Queen Mary University, London and Barts Health Trust, London, UK) and Prof. Andrew Dauber (Chief of Endocrinology, Children's National Hospital. Washington, DC, USA) as they engage in a conversation about the diagnosis and management of patients with severe primary IGF-I deficiency. This is the second video podcast episode in a two-part series on patients with severe short stature. Prefer to watch as well as listen? Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/pe-connect/programmes/severe-primary-igfi-deficiency/ (https://cor2ed.com/pe-connect/programmes/severe-primary-igfi-deficiency/) Or go to the video on YouTube: https://youtu.be/7sNGzJRzv7g (https://youtu.be/7sNGzJRzv7g) This Podcast is endorsed by the Magic Foundation.Find out more on their website: https://www.magicfoundation.org/ (https://www.magicfoundation.org/) The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. This podcast is developed by COR2ED.com (https://cor2ed.com/)

10. 

    6 Dec 2023

    Short stature: Key challenges in diagnosis and management. Part 1

    Do you know how to differentiate between growth hormone deficiency (or GHD) and primary IGF-I deficiency (or growth hormone resistance) and the key challenges in the diagnosis and management of patients with short stature conditions? For children presenting with short stature, an early and correct diagnosis is essential to allow children to achieve their full growth potential with appropriate treatment. Listen as expert pediatric endocrinologists delve into these rare growth disorders. Join Prof. Philippe Backeljauw (Professor at Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, USA) and Prof. Dr. Joachim Woelfle (Chairman of Pediatrics, Director of the Department of Pediatric and Adolescent Medicine at the Friedrich Alexander University Erlangen, Germany) as they engage in a conversation regarding key challenges in the diagnosis and management of patients with short stature conditions. The experts discuss the incidence of patients with GHD and severe primary IGF-I deficiency and how to differentiate these conditions based on clinical presentation as well as biochemical and genetic testing. The importance of taking a good medical history and physical examination is discussed, as well as various caveats related to biochemical and genetic testing. Regional differences in the diagnosis of these patients are covered as well as key challenges in the diagnosis and management. Finally, the experts discuss the different treatment options as well as the importance of ensuring caregivers are well-informed regarding the efficacy and safety of the respective treatments. This is the first video podcast episode in a two-part series on patients with severe short stature. Prefer to watch as well as listen? Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/pe-connect/programmes/rare-growth-disorders-podcast/ (https://cor2ed.com/pe-connect/programmes/rare-growth-disorders-podcast/) Or go to the video on YouTube: https://youtu.be/OfI3lZgjew0 (https://youtu.be/OfI3lZgjew0) Download the transcript: https://cor2ed.com/pe-connect/programmes/rare-growth-disorders-podcast/ (https://cor2ed.com/pe-connect/programmes/rare-growth-disorders-podcast/) This Podcast is endorsed by the Magic Foundation. Find out more on their website: https://www.magicfoundation.org/ (https://www.magicfoundation.org/) The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. This podcast is developed by COR2ED.com (https://cor2ed.com/)

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Spotify

4.8 / 5

4,023 ratings

Contact Rare Diseases Medical Conversation Video

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.